SEARCH:   Advanced

Blood, 15 June 2005, Vol. 105, No. 12, pp. 4784-4791. Prepublished online as a Blood First Edition Paper on February 24, 2005; DOI 10.1182/blood-2004-11-4201. This Article Full Text (PDF) All Versions of this Article: 2004-11-4201v1 105/12/4784    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ladetto, M. Articles by Boccadoro, M. Search for Related Content PubMed PubMed Citation Articles by Ladetto, M. Articles by Boccadoro, M. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted November 3, 2004 Accepted February 10, 2005 Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome Marco Ladetto*, Sonia Vallet, Andreas Trojan, Maria Dell'Aquila, Luigia Monitillo, Rosalba Rosato, Loredana Santo, Daniela Drandi, Alessandra Bertola, Patrizia Falco, Federica Cavallo, Irene Ricca, Federica De Marco, Barbara Mantoan, Beata Bode-Lesniewska, Gloria Pagliano, Roberto Francese, Alberto Rocci, Monica Astolfi, Mara Compagno, Sara Mariani, Laura Godio, Lydia Marino, Marina Ruggeri, Paola Omede, Antonio Palumbo, and Mario Boccadoro Divisione di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale, Universita di Torino, Azienda Ospedaliera San Giovanni Battista, Torino, Italy Department of Oncology, University Hospital, Zurich, Switzerland Servizio di Epidemiologia dei Tumori e Biostatistica, Universita di Torino, Azienda Ospedaliera San Giovanni Battista, Torino, Italy Department of Pathology, University Hospital, Zurich, Switzerland Divisione di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale, Universita di Torino, Azienda Ospedaliera San Giovanni Battista, Torino, Italy; Centro di Ricerca in Medicina Sperimentale (CERMS), Ospedale San Giovanni Battista, Torino, Italy Divisione di Anatomia Patologica, Dipartimento di Scienze Biomediche ed Oncologia Umana, Universita di Torino, Azienda Ospedaliera San Giovanni Battista, Torino, Italy * Corresponding author; email: marco.ladetto{at}unito.it. COX-2 is an inflammation-associated enzyme involved in the pathogenesis of many solid tumors, but little is known about its presence and role in hematological neoplasms. Multiple myeloma (MM) is known to involve a deregulated cytokine network with secretion of inflammatory mediators. We thus decided to investigate the involvement of COX-2 in this neoplasm. 142 bone marrow (BM) specimens, including MM and MGUS, were evaluated by Western blotting (WB). Selected cases underwent further evaluation by WB on purified CD138 positive cells, immunohistochemistry (IC) and real time PCR for mRNA expression. COX-2 was expressed in 11% (2 of 18) of MGUS specimens, 31% (29 of 94) of MM at diagnosis and 47% (14 of 30) of MM with relapsed/refractory disease. COX-2 positivity was associated with a poor outcome in terms of progression-free (18 vs. 36; months, p<0.001) and overall survival (28 vs. 52 months, p<0.05). Real-time PCR showed COX-2 mRNA over-expression. IC and cell separation studies demonstrated COX-2 expression to be restricted to malignant plasma cells. This is the first report of the presence and prognostic role of COX-2 expression in MM. Future studies will assess COX-2 involvement in other hematological tumors and its potential use as a therapeutic or chemo-preventive target in onco-hematology. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: F. Silvestris, P. Cafforio, M. De Matteo, N. Calvani, M. A. Frassanito, and F. Dammacco Negative Regulation of the Osteoblast Function in Multiple Myeloma through the Repressor Gene E4BP4 Activated by Malignant Plasma Cells Clin. Cancer Res., October 1, 2008; 14(19): 6081 - 6091. [Abstract] [Full Text] [PDF] E. P. Ryan, C. M. Malboeuf, M. Bernard, R. C. Rose, and R. P. Phipps Cyclooxygenase-2 Inhibition Attenuates Antibody Responses against Human Papillomavirus-Like Particles J. Immunol., December 1, 2006; 177(11): 7811 - 7819. [Abstract] [Full Text] [PDF] B. Hoang, L. Zhu, Y. Shi, P. Frost, H. Yan, S. Sharma, S. Sharma, L. Goodglick, S. Dubinett, and A. Lichtenstein Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance Blood, June 1, 2006; 107(11): 4484 - 4490. [Abstract] [Full Text] [PDF] V. R. Holla, J. R. Mann, Q. Shi, and R. N. DuBois Prostaglandin E2 Regulates the Nuclear Receptor NR4A2 in Colorectal Cancer J. Biol. Chem., February 3, 2006; 281(5): 2676 - 2682. [Abstract] [Full Text] [PDF] A. Kardosh, N. Soriano, Y.-T. Liu, J. Uddin, N. A. Petasis, F. M. Hofman, T. C. Chen, and A. H. Schonthal Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib Blood, December 15, 2005; 106(13): 4330 - 4338. [Abstract] [Full Text] [PDF] H M. Prince, L. Mileshkin, A. Roberts, V. Ganju, C. Underhill, J. Catalano, R. Bell, J. F. Seymour, D. Westerman, P. J. Simmons, et al. A Multicenter Phase II Trial of Thalidomide and Celecoxib for Patients with Relapsed and Refractory Multiple Myeloma Clin. Cancer Res., August 1, 2005; 11(15): 5504 - 5514. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020